Register now for winter and spring MORE THAN PINK Walk and Race for the Cure events. Your support will provide hope and help to those affected by breast cancer. Ending breast cancer needs all of us! https://bit.ly/3SMf8Rm
Susan G. Komen
非盈利组织
Dallas,Texas 50,697 位关注者
A force united by a promise to end breast cancer, funding groundbreaking research, community health & advocacy programs.
关于我们
In 1980, Nancy G. Brinker promised her dying sister, Susan, that she would do everything in her power to end breast cancer forever. Two years later, that promise became the Susan G. Komen? organization and the beginning of a global movement. For over 40 years, we've led the way funding groundbreaking research, community health initiatives and advocacy programs in local communities across the U.S. and in more than 30 countries. And with your help, we’ll continue pushing for progress to end breast cancer every day, until it’s a thing of the past. For information on breast cancer and breast health, please call: 1-877- GO KOMEN or visit https://komen.org/ Join us on social media: Facebook: www.facebook.com/SusanGKomen Twitter: www.twitter.com/SusanGKomen Instagram: @SusanGKomen Pinterest: www.pinterest.com/SusanGKomen Blog: blog.komen.org
- 网站
-
https://www.komen.org
Susan G. Komen的外部链接
- 所属行业
- 非盈利组织
- 规模
- 201-500 人
- 总部
- Dallas,Texas
- 类型
- 非营利机构
- 创立
- 1982
- 领域
- nonprofit、breast cancer、health、education、prevention、susan g. komen for the cure、race、cancer和health equity
地点
-
主要
13770 Noel Road
Ste 801889
US,Texas,Dallas,75380
Susan G. Komen员工
动态
-
"Don’t hesitate to ask for more information, seek additional resources and trust your gut. You always need to advocate for yourself,” says Dawn, a breast cancer survivor, wife and mother of two. Dawn's story is a testament to the importance of utilizing online resources, asking questions and seeking second opinions when it comes to your diagnosis and treatment. Read more: https://bit.ly/40Y3lFR
-
Frances is an advocate for yearly mammograms. She had promised her mother that when she turned 40, she would get her mammogram yearly, and this was a promise she kept. In 2017, when Frances was 60, her mammogram came back abnormal. After a series of tests, Frances learned she had stage 2B triple-positive breast cancer. Frances remembers the promise she made to her mother and encourages others to always get their mammograms. “Our bodies have a lot to do with our health and we neglect the warning signs sometimes,” she said. “But getting your mammogram is so important.” For more on her story read here: https://bit.ly/40FIvek
-
Join CURE and Susan G. Komen for one of our many upcoming, in-person “Educated Patient” events to learn the latest about metastatic breast cancer resources and care. Find dates, locations https://lnkd.in/gTYSWC78
-
Right now more than ever, breast cancer patients need your support. This #GivingTuesday, breast cancer patients need your help. Ford Motor Company Warriors in Pink are matching all donations 4x. Join our fight. Save lives. https://bit.ly/3V21X1i
-
Make a commitment to the fight against breast cancer in 2025 by joining us at a Komen 3-Day Walk. You will love it in the pink bubble walking 20, 40 or 60 miles with others who share your passion for supporting research, patient care and advocacy. Hurry: you can register for just $25 through Dec. 31 with the code KOMEN2025. www.the3day.org
-
Did you know that BCRA gene mutations can increase the risk of not just breast cancer, but many other cancers as well? That's why it's so important to know your family history to take charge of your health. Join us at 3pm CST on Thursday, November 21 for a Facebook Live in partnership with Johnson & Johnson to learn more about BCRA gene mutations and how to have tough family conversations about genetic testing and counseling.
-
Results from a Komen-supported phase 1 clinical trial testing a new vaccine in triple negative breast cancer were just published by Dr. William Gillanders. Dr. Gillanders & colleagues found that the vaccine was well-tolerated and was able to activate the immune system to target the unique tumor mutations specific to each participant. Read more about the study here: https://bit.ly/3CGlRs8